Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Egens Biotech Gains Rights to Hepatitis C Diagnostic from Israel's BATM

publication date: Jun 30, 2016
Jiangsu Egens Biotechnology has in-licensed China rights to a hepatitis C diagnostic test from BATM, an Israeli networking technology company with a diagnostic subsidiary, Adaltis. In 2014, Egens and Adaltis set up a China JV to import diagnostic products. The CFDA approved Adaltis' hepatitis C diagnostic in 2015, and the JV has contracted with Sinopharm to distribute the device in China. Egens says it combines biological material development, diagnostic reagent manufacturing and trade. More details....

Stock Symbol: (LSE: BVC)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here